scholarly journals Thoracoscopic lobectomy for non-small-cell lung cancer in patients with impaired pulmonary function: analysis from a national database

2020 ◽  
Vol 30 (6) ◽  
pp. 803-811
Author(s):  
Stefano Bongiolatti ◽  
Alessandro Gonfiotti ◽  
Eduart Vokrri ◽  
Sara Borgianni ◽  
Roberto Crisci ◽  
...  

Abstract OBJECTIVES The objective of this retrospective multi-institutional study was to evaluate the postoperative outcomes of video-assisted thoracoscopic surgery (VATS)-lobectomy (VATS-L) for non-small-cell lung cancer (NSCLC) in patients with impaired lung function. The second end point was to illustrate the effective role of forced expiratory volume in 1 s (FEV1%) and the diffusing capacity of the lung for carbon monoxide (DLCO%) in predicting complications in this population. METHODS Data from patients who underwent VATS-L at participating centres were analysed and divided into 2 groups: group A comprised patients with FEV1% and/or DLCO% >60% and group B included patients with impaired lung function defined as FEV1% and/or DLCO% ≤60%. To define clinical predictors of death and complications, we performed univariate and multivariable regression analyses. RESULTS A total of 5562 patients underwent VATS-L, 809 (14.5%) of whom had impaired lung function. The postoperative mortality rate did not differ between the 2 groups (2.3% vs 3.2%; P = 0.77). The percentage of patients who had any complication (21.4% vs 34.2%; P ≤ 0.001), the complication rate (28% vs 49.8%; P ≤ 0.001) and the length of hospital stay (P ≤ 0.001) were higher for patients with limited pulmonary function. Impaired lung function was a strong predictor of overall and pulmonary complications at multivariable analysis. CONCLUSIONS VATS-L for NSCLC can be performed in patients with impaired lung function without increased risk of postoperative death and with an acceptable incidence of overall and respiratory complications. Our analysis suggested that FEV1% and DLCO% play a substantial role in estimating the risk of complications after VATS-L, but their role was less reliable for estimating the mortality.

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xiyue Zhang ◽  
Wei Li ◽  
Chunyan Li ◽  
Jie Zhang ◽  
Zhenzhong Su

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with unclear pathogenesis. IPF is considered as a risk factor for lung cancer. Compared to other lung cancers, small-cell lung cancer (SCLC) has a lower incidence, but has a more aggressive course. Patients with IPF and SCLC have a lower survival rate, more difficult treatment, and poorer prognosis. Case presentation Case 1 was of a 66-year-old man with IPF for 5 years, who was admitted to our hospital for dyspnea. Case 2 was of a 68-year-old woman, who presented with chest pains, cough, and dyspnea. Both patients had extremely poor lung function. High-resolution computed tomography and pathology revealed that both patients had IPF and SCLC. Chemotherapy comprising nedaplatin (80 mg/m2) and etoposide (100 mg for 5 days) was initiated for both patients. Antifibrotic agents were continued during the chemotherapeutic regimen. Both patients showed improvement in their condition after treatment. Conclusion The favorable outcomes in these 2 cases suggests that chemotherapy is worth considering in the management of patients having SCLC and IPF with poor lung function.


Brachytherapy ◽  
2017 ◽  
Vol 16 (3) ◽  
pp. S93-S94
Author(s):  
Xiaodong Huo ◽  
Bin Huo ◽  
Haitao Wang ◽  
Shude Chai ◽  
Lei Wang ◽  
...  

CHEST Journal ◽  
2009 ◽  
Vol 135 (6) ◽  
pp. 1588-1595 ◽  
Author(s):  
M. Patricia Rivera ◽  
Frank C. Detterbeck ◽  
Mark A. Socinski ◽  
Dominic T. Moore ◽  
Martin J. Edelman ◽  
...  

2019 ◽  
Vol 47 (1) ◽  
pp. 583-592 ◽  
Author(s):  
Monika Migdalska-Sęk ◽  
Katarzyna Góralska ◽  
Sławomir Jabłoński ◽  
Jacek Kordiak ◽  
Ewa Nawrot ◽  
...  

Abstract A pro-inflammatory cytokine, IL-17A, is associated with increased risk of developing numerous cancers, including non-small cell lung cancer (NSCLC). IL-17A is a target gene for miR-9. This encouraged us to analyze these two genes in terms of their usefulness as prognostic markers in NSCLC. The expression levels of IL-17A gene and miR-9 was assessed in 26 NSCLC tissue samples and 26 unchanged lung tissue adjacent to lung tumors (control tissue), using qPCR. In both tissue groups, a decreased expression of IL-17A was observed in 100% of samples. Increased expression of miRNA-9 was observed in 92% of tumor samples, and in 100% of control samples. Neither statistical differences in the level of expression IL-17A depending on the patient’s age, gender, smoking status, nor histopathology of the cancer was found. Regarding the presence of nodule metastasis (‘N’ value in TNM classification), significantly lower expression level of IL-17A was observed in cN2 as compared with cN1 group. Additionally, statistically lower IL-17A expression was found in III versus II tumor stage (cAJCC classification). Significant negative correlation between both studied genes was revealed in SCC subgroup. This leads to the conclusion that miRNA-9 can regulate the expression of IL-17A as an IL-17A mRNA antagonistic mediator. Inhibition of proinflammatory action of IL-17A in correlation with tumor progression can be related to various activity of Th17 cells on cancer development according to its immunogenicity, and also may suggest suppressive role of IL-17A in tumor progression. However, because of low number of analyzed samples, further studies on the functional role of IL-17A in development and/or progression NSCLC seem warranted.


2019 ◽  
Vol 11 (11) ◽  
pp. 4562-4572
Author(s):  
Suk-young Lee ◽  
Yoon Ji Choi ◽  
Jae Hong Seo ◽  
Sung Yong Lee ◽  
Jung Sun Kim ◽  
...  

Author(s):  
Ramesh Gopal ◽  
George Starkschall ◽  
Susan L Tucker ◽  
James D Cox ◽  
Zhongxing Liao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document